U.S. markets closed
  • S&P Futures

    4,430.25
    -2.75 (-0.06%)
     
  • Dow Futures

    34,746.00
    +3.00 (+0.01%)
     
  • Nasdaq Futures

    15,170.00
    -24.75 (-0.16%)
     
  • Russell 2000 Futures

    2,275.80
    -1.20 (-0.05%)
     
  • Crude Oil

    75.61
    +0.16 (+0.21%)
     
  • Gold

    1,752.40
    +0.40 (+0.02%)
     
  • Silver

    22.66
    -0.04 (-0.17%)
     
  • EUR/USD

    1.1693
    -0.0008 (-0.07%)
     
  • 10-Yr Bond

    1.4840
    +0.0240 (+1.64%)
     
  • Vix

    18.76
    +1.01 (+5.69%)
     
  • GBP/USD

    1.3699
    -0.0006 (-0.04%)
     
  • USD/JPY

    111.0900
    +0.1120 (+0.10%)
     
  • BTC-USD

    42,562.86
    -1,667.63 (-3.77%)
     
  • CMC Crypto 200

    1,053.64
    -47.88 (-4.35%)
     
  • FTSE 100

    7,063.40
    +11.92 (+0.17%)
     
  • Nikkei 225

    30,012.44
    -227.62 (-0.75%)
     

15 Words From Vertex's CEO That Signal Major Growth Ahead

·4 min read
15 Words From Vertex's CEO That Signal Major Growth Ahead
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Here's the one big worry a lot of investors have about Vertex Pharmaceuticals (NASDAQ: VRTX) these days: revenue prospects beyond its main cystic fibrosis (CF) business. Vertex is moving candidates through the pipeline in other areas such as blood disorders, pain, and a rare lung and liver disorder called alpha-1 antitrypsin deficiency. Of course, as a shareholder I'd like to see Vertex bring one or more of those potential products to market.